Pharmafile Logo
Pharmafocus logo
Advanced Search

lung cancer

Showing 15 posts of 193 posts found.

headquarters_ingelheim3

Additional data for Boehringer’s Giotrif combo shows strong overall survival benefit in lung cancer sub-population

August 5, 2019
Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, giotrif, lung cancer, pharma

German firm Boehringer Ingelheim has released new interim data from a real-world evidence study investigating the efficacy of Giotrif/Gilotrif (afatinib) …

News
images

Roche’s Tecentriq combo recommended in Europe for non-small cell lung cancer

July 29, 2019
Sales and Marketing Cancer, NSCLC, Roche, lung cancer, pharma, tecentriq

Riche’s blockbuster immunotherapy Tecentriq (atezolizumab) is closing in on securing yet another approval after it revealed that the drug was …

News
opdivo_1_1

BMS’ blockbuster Opdivo flies high and falls short in non-small cell lung cancer

July 25, 2019
Research and Development Bristol-Myers Squibb, NSCLC, immuntherapy, lung cancer, opdivo, pharma

Bristol-Myers Squibb has pulled back the veil on new data from two analyses of its blockbuster immunotherapy Opdivo (nivolumab) in …

News
astrazeneca_plaque

AstraZeneca’s Imfinzi gets orphan drug designation from FDA

July 12, 2019
Medical Communications AstraZeneca, Cancer, Imfinzi, lung cancer, pharma

AstraZeneca’s cancer immunotherapy Imfinzi has been granted orphan drug status as a treatment for small cell lung cancer (SCLC). The …

News

NICE recommends Pfizer’s Vizimpro, rejects AstraZeneca’s Tagrisso, in non-small cell lung cancer

July 5, 2019
Medical Communications, Sales and Marketing Cancer, NHS, NICE, Pfizer, UK, Vizimpro, lung cancer, pharma

NICE has announced its decision to recommend Pfizer’s Vizimpro (Dacomitinib) in the treatment of non-small-cell lung cancer (NSCLC) – a …

News
merck-keytruda

MSD’s Keytruda snatches up first approval in small cell lung cancer

June 19, 2019
Research and Development, Sales and Marketing Cancer, FDA, MSD, US, keytruda, lung cancer, pharma

MSD has revealed that its anti-PD-1 immunotherapy Keytruda (pembrolizumab) has been awarded marketing authorisation from the FDA as a monotherapy …

News
merckentranceweb

Longest follow up trial of Merck’s Keytruda sets new standard for five year survival in lung cancer

June 3, 2019
Sales and Marketing KEYNOTE, MSD, Merck, keytruda, lung cancer

Nearly a quarter of previously untreated lung cancer patients who took Keytruda (Pembrolizumab) were alive after five years, according to …

News

AI better than radiologists at diagnosing lung cancer

May 21, 2019
Manufacturing and Production AI, artificial intelligence, cancer screening, lung cancer, pharma ML

An artificial intelligence (AI) is better than specialist doctors at diagnosing lung cancer, according to a study from researchers at …

News

Pfizer scores conditional European approval in ALK-positive lung cancer with Lorviqua

May 8, 2019
Research and Development Cancer, Europe, Lorviqua, NSCLC, Pfizer, lung cancer, pharma

Pfizer’s Lorviqua (lorlatinib), or Lorbrena as it is known in the US, Canada and Japan, has just been awarded conditional …

News
merckwindow_web

FDA expands Keytruda label to include stage 3 and 4 non-small cell lung cancer

April 12, 2019
Medical Communications, Research and Development Cancer, MSD, keytruda, lung cancer, non-small cell lung cancer, pharma

MSD has revealed that its anti-PD-1 therapy Keytruda (pembrolizumab) has received expanded indication from the FDA to include the first-line …

News

European approval for Pfizer’s Vizimpro in first-line non-small cell lung cancer

April 4, 2019
Sales and Marketing Cancer, Europe, Pfizer, Vizimpro, lung cancer, non small cell lung cancer, non-small cell lung cancer, pharma

The European Commission has awarded marketing approval to Pfizer’s tyrosine kinase inhibitor (TKI) Vizimpro (dacomitinib), it has emerged, as a …

News
merckwindow_web

China approves Keytruda for non-small cell lung cancer

April 2, 2019
Manufacturing and Production China, MSD, Merck and Co, USA, keytruda, lung cancer, pharma

US firm MSD has won approval for Keytruda in China. The cancer immunotherapy has thus become the first PD-1 inhibitor …

News

AstraZeneca’s Imfinzi to be made available via Cancer Drugs Fund in England

March 28, 2019
Sales and Marketing AstraZeneca, Cancer, Imfinzi, NHS, NICE, UK, lung cancer

AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) will now be made available to English lung cancer patients on the NHS via the …

News

Roche’s Tecentriq chalks up another FDA approval, this time in first-line extensive-stage small cell lung cancer

March 20, 2019
Research and Development, Sales and Marketing FDA, Roche, lung cancer, pharma, tecentriq

Roche has secured another US approval for its immunotherapy Tecentriq (atezolizumab), as the FDA reveals its approval of the drug …

News
merckwindow_web

MSD’s Keytruda/chemo combo nabs EU approval in first-line metastatic squamous lung cancer

March 15, 2019
Medical Communications, Sales and Marketing Cancer, MSD, NSCLC, keytruda, lung cancer, pharma

MSD’s anti-PD-L1 therapy Keytruda (pembrolizumab) has been awarded marketing authorisation in Europe for the first-line treatment of adult patients with …

News

Latest content

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024